Navigation Links
BioMS Medical Announces First quarter 2009 results
Date:5/11/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, May 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter, ended March 31, 2009.

"We remain on track to obtain the results from MAESTRO-01, the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," said Kevin Giese, President and CEO of BioMS Medical. "We have demonstrated in previous trials that dirucotide has shown to be well tolerated and has the capacity to slow the progression of disease in certain genetically pre-disposed MS patients. If our pivotal trials confirm these results, we believe dirucotide could represent the first drug with blockbuster potential for the treatment of secondary progressive multiple sclerosis."

Currently, BioMS is conducting two pivotal clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

    -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
       phase III trial, being conducted in Canada and Western Europe, had
       completed full recruitment of 611 SPMS patients at 47 trial sites in
       ten countries. The primary clinical endpoint for MAESTRO-01 (and
       MAESTRO-03) is defined as a statistically and clinically significant
       increase in the time to progression of the disease as measured by the
       Expanded Disability Status Scale (EDSS), in patients with HLA-DR2
       and/or HLA-DR4 immune response genes.

       On April 21, 2009 the DSMB conducted a scheduled safety analysis and
       recommended that the trial continue to completion. To date, there have
       been ten positive safety reviews from the Data Safety Monitoring Board
       (DSMB) and this was the final scheduled review by 
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioMS Medical to present at Alberta Economic Forum in Geneva
2. BioMS Medical to present at BioFinance 2009
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical Announces 2008 Year End Results
6. BioMS Medical warrant extension
7. BioMS Medical to present at BIO CEO and Investor Conference
8. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
9. BioMS Medical recognized at Scrip Awards 2008
10. BioMS Medical Announces Third Quarter 2008 Results
11. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 SoundConnect ... collaboration company, is proud to announce the addition ... complements Adobe Connect’s elearning tools to quickly deploy ... content with training tools for desktop and mobile ... LMS is the perfect online training solution, enabling ...
(Date:7/30/2014)... 2014 Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended June 30, 2014 on Wednesday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its second quarter ...
(Date:7/30/2014)... , July 30, 2014 A ... evaluated the safety and efficacy of CSL Behring,s ... following kidney transplants in highly sensitized patients. C1-INH ... of the complement system. The study ... significant increases in the levels of complement components ...
(Date:7/30/2014)... Selexis SA , a serial innovation ... mammalian cell line development, announced today new data from ... presented at the 10th Annual Cell Line Development ... 10, 2014 at the Double Tree by Hilton Berkeley ... will be presented during an oral presentation: , Title: ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... LEUVEN, Belgium and LUND, Sweden, September 7 ... Anticoagulant Into Phase,II Clinical Development ThromboGenics NV ... disease, and co-development partner, BioInvent,International (Nordic Exchange: BINV), ... initial follow-up of all volunteers,in the first Phase ...
... 6 Globally, approximately 418 billion,people are currently ... costs of hepatitis in the 21st century cannot ... a,new report by Kalorama Information. Paradoxically, despite ... necessary steps to contain hepatitis. Yet the incidence ...
... VRUS ) and Roche (OTC: RHHBY) announced ... the treatment of chronic hepatitis C,virus (HCV) will ... Hepatitis C,Virus and Related Viruses being held from ... of PSI-6130, is an oral cytidine nucleoside,analog polymerase ...
Cached Biology Technology:ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 5Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
(Date:7/30/2014)... knows the shortest distance between two points is a ... sperm have been taking the familiar axiom to heart. ... thought to be intense, with each racing for the ... some species, sperm form cooperative groups that allow them ... , A new study, conducted by Heidi Fisher, a ...
(Date:7/30/2014)... the University of Helsinki and the Universitat Autnoma de ... morphological changes which have taken millions of years to ... development of mice teeth, induced in the laboratory, scientists ... those observed in the fossil registry of rodent species ... , To modify the development of their teeth, the ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2When cooperation counts 2When cooperation counts 3Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... It,s long been known that alcohol use in ... birth defects, but researchers who study fetal alcohol syndrome ... disorder, detecting it early, or effectively treating it, say ... the issue of Developmental Neuroscience , four first-year ...
... How do we begin to understand what early life was ... planet shifted from an oxygen-free and probably ice-covered realm to ... who decodes the early record of life on Earth has ... a significantly clearer picture of this dynamic environment. Alison Olcott ...
... , THE WOODLANDS, Texas , June 15 ... company focused on discovering breakthrough treatments for human disease, announced today ... clinical trial of LX4211 for patients with type 2 ... June 19 – 22, 2010 in San Diego, ...
Cached Biology News:Little is understood about alcohol's effect on fetal development, Georgetown researchers say 2Little is understood about alcohol's effect on fetal development, Georgetown researchers say 3Delineating primary and secondary organic carbon in neoproterozoic glacial sediments 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 3Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 4Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 5
... Experion HighSens analysis kit for 25 chips ... perform high-sensitivity RNA analysis (at picogram levels) ... kit includes 25 RNA HighSens microfluidic chips, ... x 20 microliters RNA HighSens stain, 20 ...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... The Experion StdSens analysis kit for ... required to perform standard-sensitivity RNA analysis (at ... system. This kit includes 25 RNA StdSens ... gel, 2 x 20 microliters RNA StdSens ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White ... GAS. A brain-permeable and water soluble pyrimidinone ... NAD + -competitive inhibitor of PARP (IC ... nM for rhPARP1 and rmPARP2, respectively) with ...
Biology Products: